From April 1, 2024 to April 3, 2024, the company has repurchased 6,479,843 shares, representing 0.8% for CNY 154.55 million. With this, the company has completed the repurchase of 24,242,904 shares, representing 3% for CNY 500 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.17 CNY | +1.81% | +2.03% | +26.72% |
May. 24 | Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024 | CI |
Apr. 26 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.72% | 3.01B | |
-7.10% | 180B | |
-0.32% | 109B | |
-2.95% | 68.93B | |
-5.11% | 46.41B | |
+12.31% | 45.43B | |
+7.38% | 43.26B | |
+16.31% | 30.05B | |
+16.10% | 25.19B | |
-7.48% | 23.34B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.